AUS
NZ
UK
CA
USA
IND
Highlights
- New Contracts: Five commercial data partnership agreements in 2024, totaling £1.13 million in first-year contract value.
- Revenue Growth: Contributions already bolstering 2024 revenue and Annual Recurring Revenue (ARR).
- Strategic Expansion: Broader customer reach via marketplaces and co-selling models.
Diaceutics PLC (LSE:DXRX), a leading provider of technology and solutions for the pharmaceutical and biotech industries, announced significant strides in its US commercial strategy. During 2024, the company executed five commercial data partnership agreements, including one in H1 and four in H2, collectively valued at £1.13 million ($1.48 million) for the first year.
These agreements are already contributing to revenue growth in 2024 and enhancing Annual Recurring Revenue (ARR), positioning the company for sustained financial success.
Leveraging Partnerships for Market Expansion
The partnerships focus on integrating Diaceutics’ data products, such as the high-margin DXRX Signal, into marketplaces and utilizing partner sales teams through a co-selling approach. This model enables Diaceutics to scale its commercial reach by targeting a wider customer base, including new pharmaceutical brands and untapped customer segments.
According to the company’s directors, this strategy represents a pivotal move to expand its footprint within the competitive US market, capitalizing on the growing demand for data-driven solutions in the pharma and biotech sectors.
